China (Mainland)
Premiumsupplier 
CCG1423, CAS NO.285986-88-1
- FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
- Min.Order: 100 Gram
- Payment Terms: L/C
- Available Specifications:
≥98.0%(100-500)Gram≥98.0%(1000-5000)Gram
- Product Details
Keywords
- CCG1423,
- CCG-1423;N-(2-(4-Chloroanilino)-1-Methyl-2-oxoethoxy)-3,5-bis(trifluoroMethyl)benzaMide;N-(1-(4-chlorophenylaMino)-1-oxopropan-2-yloxy)-3,5-bis(trifluoroMethyl)benzaMide;N-({1-[(4-Chlorophenyl)Amino]-
- 285986-88-1
Quick Details
- ProName: CCG1423,
- CasNo: 285986-88-1
- Molecular Formula: C18H13ClF6N2O3
- Appearance: White crystal
- Application: CAS：285986-88-1； Small molecule inhib...
- DeliveryTime: 2 months
- PackAge: 100g,500g,1kg,25kg/drum
- Port: shang hai
- ProductionCapacity: 1000 Gram/Week
- Purity: 98%
- Storage: Dry seal
- Transportation: shipping
- LimitNum: 100 Gram
Superiority
Details
CCG-1423 is a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis.
IC50 value: 1.5 uM [1]
Target: Rho signaling inhibitor
in vitro: CCG-1423 selectively inhibited spontaneous PC-3 prostate cancer cell invasion through a Matrigel matrix, but not the Gαi-dependent LPA-stimulated SKOV-3 ovarian cancer cell invasion, in vitro. At 100 μM, nearly complete inhibition of invasion was achieved with a lesser degree of toxicity than that induced by CCG-1423 at 10 μM [1]. SRF binds to this site in vivo and the SRF inhibitor CCG-1423 completely blocks STARS proximal reporter activity in H9c2 cells [3]. pharmacological MKL-inhibition with CCG-1423 significantly inhibited CCN1 promoter activity as well as mRNA and protein expression[4].
in vivo: Pharmacological SRF inhibition by CCG-1423 reduced nuclear MKL1 and improved glucose uptake and tolerance in insulin-resistant mice in vivo [2].